Latest Derivatives News

DEXUS Convenience Retail REIT has announced a final distribution of AUD 0.05138 per security for the quarter ending December 2024, confirming steady income for investors ahead of the February payment date.

Dexus Convenience Retail REIT has rebounded strongly with a $14.7 million net profit for the half-year ending December 2024, underpinned by a resilient portfolio and active redevelopment plans.

Firetail Resources has identified several significant electromagnetic conductor targets at its Skyline Copper Project in Newfoundland, marking a major step forward in exploration with promising geological signatures for copper-zinc mineralisation.

Charter Hall Long WALE REIT has reversed last year’s heavy losses, reporting a statutory profit of $51.3 million for the half year ended December 2024, while maintaining steady distributions to investors.

Citigroup Global Markets Australia has announced an unfranked dividend of AUD 0.204 for its AMC CitiFirst Instalment MINIs, with key dates set for late February and mid-March 2025.

Metrics Master Income Trust has confirmed an ordinary dividend of AUD 0.0137 per security for the month ending January 31, 2025, payable on February 10. This update finalises the previously estimated payout, highlighting the trust's steady income distribution approach.

360 Capital Mortgage REIT (ASX:TCF) reported a robust HY25 performance, highlighting a forecast distribution yield of 10.2% and a successful $8.9 million capital raising that expands its loan portfolio and market presence.

Cullen Resources has identified significant, untested gold anomalies across a 25km trend at its Yardilla project in Western Australia, highlighting promising prospects for future drilling campaigns.

A new peer-reviewed study highlights Cynata Therapeutics’ Cymerus™ iPSC-derived MSCs as superior to traditional donor tissue-derived MSCs in potency, consistency, and regenerative potential.

Bio-Gene Technology Limited has secured A$3 million in U.S. Department of Defense grants to accelerate development of its two nature-derived insecticides, Flavocide and Qcide, targeting both military and civilian markets.

Emyria reports sustained and statistically significant improvements in PTSD symptoms and quality of life three months after MDMA-assisted therapy, signaling a potential breakthrough for treatment-resistant patients.

WAT Resources Ltd has successfully produced ferroniobium from its Luni niobium concentrate, marking a key milestone in the West Arunta Project’s development. The proof-of-concept testwork confirms the viability of a conventional production process and sets the stage for further optimisation and product diversification.